| IGF2 |
| LOCUS ID | 3481 | ||||||||||||||||
| GENE_SYMBOL | IGF2 | ||||||||||||||||
| GENE NAME | insulin-like growth | ||||||||||||||||
| SYNONYMNS | IGF-II, PP9974, C11orf43 | ||||||||||||||||
| CHROMOSOME | 11 | ||||||||||||||||
| HOMOLOGENE ID | 510 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| This gene encodes a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paterl allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. A read-through INS-IGF2 gene exists, whose 5' region overlaps the INS gene and the 3' region overlaps this gene. Altertively spliced transcript variants |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. The suggest the following molecular etiopathophysiology of DN(i) hyperglycemia upregulates IGF2, which initiates PTEN, a regulator of IGF2 sigling; (ii) loss of this IGF2-PTEN feedback loop causes changes that are characteristic of DN; and (iii) lowered expression of the repair modulator SPARC in the development and/or progression of DN. Hence, targeting relevant modulators, such as like IGF2, PTEN, and SPARC, may be important in the magement of DN. | 20929508 |
| Retinopathy | 1. IGF-I, IGF-II, IGF-BP3 and albumin were determined by immunological methods and were confirmed to be increased in patients with PDR compared to controls. | 11440279 |
| Neuropathy | 1. Studies with NGF, NT-3, IGF-I and IGF-II both in vitro and in animal models of neuropathies (including DPN) suggest that these factors ameliorate nerve degeneration. | 10023126 |